Hansen Medical has made several changes to its leadership team, including appointing Bruce J. Barclay as its president and CEO and to its board of directors, effective June 9.
The Mountain View, Calif.-based company said its previous CEO, Frederic H. Moll, MD, will become executive chairman of the board as Russell C. Hirsch, MD, PhD, current chairman of the board, will lead as outside director.
Currently, Barclay serves as president and CEO of SurModics and has previously held leadership positions at Guidant and was president and CEO of Vascular Architects. Under the appointment, Hansen said that Barclay has the option to purchase 1.7 million shares of its common stock. One-eighth will vest six months after the beginning of his employment with the company and the remaining will vest in 42 successive equal monthly installments, pursuant to a non-plan option grant notice and non-plan option agreement (Inducement Award).
According to Hansen, the board approves the inducement award and the award expires seven years after the start date of employment. The company has also approved Barclay for options and restricted stock under its 2006 Equity Incentive Plan.